ClinicalTrials.gg
CompletedNCT07357831Updated Aug 28, 2026

A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects

A Phase 3 interventional study of MC2-01 cream and MC2-01 vehicle in Plaque Psoriasis, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Completed at 55 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
539
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
13th of 47
539 · median 200
Started
2025
with 1 other
Phase 3
17 of 47
none open now
Registered
46th of 47
by date
Lead sponsor
1 of 47
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 13th largest by enrollment, is one of 2 that started in 2025, is one of 17 in phase 3, and was the 46th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

This is a multi-center, randomized, investigator-blinded, calcipotriol and betamethasone dipropionate gel and vehicle-controlled phase 3 clinical study to evaluate the efficacy and safety of MC2-01 cream in the treatment of Chinese plaque psoriasis to assess the efficacy and safety of MC2-01 cream in Chinese subjects aged ≥ 18 years with plaque psoriasis. This study includes a screening period, a treatment period, and a safety follow-up period.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand the objectives and requirements of this study, voluntarily participate in the clinical trial and sign the form (ICF), and be able to complete all visits as required by the protocol.
  2. Aged ≥ 18 years at the time of signing the ICF, male or female.
  3. Clinical diagnosis of plaque psoriasis with involvement of the body (trunk and/or limbs) before the first dose of this study, with a disease duration of ≥ 6 months and stable for the last 4 weeks.
  4. Subjects are required to meet the following requirements at screening and baseline:

    • BSA of psoriatic involvement on body (trunk and/or limbs) ranging from 2% to 30%, with total BSA not exceeding 30% if scalp involvement is present;
    • Body (trunk and/or limbs) PGA score of 2 or 3;
    • mPASI score ≥3.
  5. Female of (WOCBP) subjects with a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline. WOCBP and male subjects who have not received a vasectomy must agree to take at least one effective method of , including oral/implantable/injectable/transdermal contraceptive, intrauterine device, bilateral tubal ligation or occlusion, vasectomy, and barrier contraception (used correctly and throughout sexual intercourse), from the first dose of the study drug through 3 months after the last dose of the study drug. If the subject is routinely abstinent, the subject may use this form of contraception, but should choose a reliable form of contraception as mentioned above when the subject is no longer abstinent. Male subjects must not donate sperm from the first dose of the study drug until 3 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Be diagnosed with non-stable psoriasis or non-plaque psoriasis.
  2. Presence of other inflammatory skin conditions in the treatment site that may confound the investigator's assessment of psoriasis.
  3. Presence of significant pigmentary changes, scarring, sunburn, and other skin abnormalities in the treatment site that affect the assessment of psoriasis efficacy.
  4. The treatment site is expected to be excessively exposed to natural/artificial light, tanning beds, or other LEDs within 4 weeks before the baseline visit and throughout the study.
  5. Known to any component of the test product or control product.
  6. Current or prior hypercalcemia, vitamin D toxicity, severe renal insufficiency ( \<30 mL/min using the Cockcroft-Gault formula), or severe hepatic impairment (according to C classification).
  7. Systemic treatment with biological therapies.
  8. Use of systemic agents for the treatment of psoriasis or any other agents which may influence the efficacy assessment of psoriasis within 4 weeks before the baseline visit or planned use during the study.
  9. Use of psoralen plus ultraviolet A (PUVA) or ultraviolet B (UVB) phototherapy within 4 weeks before the first dose of this study or planned use during the study.
  10. Use of topical medications for the treatment of psoriasis or any other agents which may influence the efficacy assessment of psoriasis within 2 weeks before the baseline visit.
  11. Clinical signs of skin infection with bacteria, viruses, or fungi
  12. Known (HIV) infection, or , or , or syphilis.
  13. Any chronic or acute medical condition that may pose a risk to the safety of the subject, or may interfere with the assessment of safety or efficacy in this trial.
  14. Planned initiation or change in the use of an existing treatment that, in the opinion of the investigator, can affect the assessment of psoriasis efficacy.
  15. Current participation in any other interventional clinical trial; or previous participation in a pharmaceutical clinical trial within 3 months or 5 half-lives (whichever is longer) or any other interventional clinical trial within 3 months prior to the first dose of this study.
  16. Women who are pregnant, lactating, or planning to become pregnant during the study.
  17. Major surgery within 4 weeks before the baseline visit or planned major surgery during the study.
  18. Active infection requiring the application of oral or intravenous antibiotics, antifungals, or antivirals within 7 days before the baseline visit.
  19. Cancer within 5 years before the first dose of this study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
539 participants (actual)

Study arms

  • Experimental
    MC2-01 Cream

    MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks

    Drug: MC2-01 cream

  • Sham comparator
    MC2-01 Vehicle

    One application daily for 8 weeks.

    Drug: MC2-01 vehicle

  • Active comparator
    CAL/BDP Gel

    Calcipotriene/betamethasone (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.

    Drug: CAL/BDP Gel

Interventions

  • DrugMC2-01 cream

    Drug pages: Calcipotriene · Betamethasone dipropionate

    MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream

  • DrugMC2-01 vehicle

    Vehicle Cream

  • DrugCAL/BDP Gel

    calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%

06

What researchers measure

Primary outcomes

  1. Physician's Global Assessment (PGA) success rate on the body (trunk and/or limbs) after 8 weeks of treatment with MC2-01 cream compared to vehicle and CAL/BDP gel in subjects with plaque psoriasis

    Proportion of subjects who achieve PGA treatment success (defined as a score of 0 or 1 plus a minimum 2-point decrease in PGA score from baseline) on the body (trunk and/or limbs) compared to after 8 weeks of treatment Psoriasis treatment success rate is measured at week 8 by the use of a Physician Global Assessment (PGA) score. Success is defined as a decrease from Baseline of minimum 2 point on a scale from 0 - 4, where: 0 = Clear; 1 = Almost clear; 2 = Mild Plaque thickening; 3 = Moderate Plaque thickening, 4 = Severe Plaque thickening.

    Time frame: Baseline and 8-week

Secondary outcomes

  1. Percent change from baseline in mPASI after 8 weeks of treatment

    To evaluate the improvement in Modified Psoriasis Area and Severity Index (mPASI) after 8 weeks of treatment with MC2-01 cream compared to vehicle and CAL/BDP gel in subjects with plaque psoriasis. The extent and severity of the participant's psoriasis is assessed using a modified PASI scoring system (minus scalp, face, and flexures) at each 3 areas (arms, trunk and legs) using a scale from 0 - 6, where 0 = no psoriasis involvement and 6 = 90-100% involvement.

    Time frame: Baseline and 8-week

  2. Assessment of Psoriasis Treatment Convenience Scale (PTCS) at week 8 of treatment

    Subject assessment of treatment convenience using a Psoriasis Treatment Convenience Scale is defined as a sum of questions 1-5, where each question is scored on a scale from 1-10. How easy was the treatment to apply to the skin? "Very difficult" is 1 and "Very easy" is 10 How greasy was the treatment when applying it to the skin? "Very greasy" is 1 and "Not greasy" is 10 How moisturised did your skin feel after applying the treatment? "Not moisturized" is 1 and "Very moisturized" is 10 How greasy did your skin feel after applying the treatment? "Very greasy" is 1 and "Not greasy" is 10 How much did treating your skin disrupt your daily routine? "Very disturbing" is 1 and "Not disturbing" is 10.

    Time frame: 8-week

  3. PGA success rate on the scalp psoriasis after 8 weeks of treatment with MC2-01 cream compared to vehicle and CAL/BDP gel in subjects with plaque psoriasis

    Proportion of subjects with scalp psoriasis involved, PGA ≥2 and ≥0.3% body surface area (BSA) at baseline who achieve PGA treatment success on the scalp psoriasis after 8 weeks of treatment

    Time frame: Baseline and 8-week

  4. Safety with MC2-01 cream in subjects with plaque psoriasis

    Number of participants with adverse events and serious adverse events will be assessed.

    Time frame: 8-week

  5. Incidence of local skin reactions

    Number of subjects that experience an local skin reactions by investigator assessment and local skin reactions reported as adverse events will be assessed

    Time frame: 8 week

  6. Number of Participants With Abnormal Electrocardiogram (ECG) Findings

    Single measurements of 12-lead ECGs were obtained at Baseline to week 8, at any visit post-screen using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc).

    Time frame: 8 week

  7. Number of Participants With Vital Signs of Potential Clinical Importance

    Body Temperature, Respiration, Pulse, and Blood Pressure were collected from participants for evaluation of vital signs by Potential Clinical Importance Criteria from Baseline to Week 8, any visit post-screen.

    Time frame: 8 week

07

Study locations

55 sites
  • The Second Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui, China
  • Beijing Aerospace General Hospital
    Beijing, Beijing Municipality, China
  • Bejjing Friendship Hospital,Capital Medical University
    Beijing, Beijing Municipality, China
  • Chongqing Hospital of Traditional Chinese Medicine
    Chongqing, Chongqing Municipality, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian, China
  • The Second Affiliated Hospital of Xiamen medical college
    Xiamen, Fujian, China
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong, China
  • Southern Medical University Dermatology Hospital
    Guangzhou, Guangdong, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
  • Sun Yat-sen University Third Affiliated Hospital
    Guangzhou, Guangdong, China
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • Shenzhen Nanshan District People's Hospital
    Shenzhen, Guangdong, China
  • Shenzhen Second People's Hospital
    Shenzhen, Guangdong, China
  • The First Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi, China
  • Haikou Fifth People's Hospital
    Haikou, Hainan, China
  • Chengde Medical University Affiliated Hospital
    Chengde, Hebei, China
  • First Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang, China
  • Henan University of Science and Technology Second Affiliated Hospital
    Luoyang, Henan, China
  • Nanyang Central Hospital
    Nanyang, Henan, China
  • Sanmenxia Central Hospital
    Sanmenxia, Henan, China
  • Zhengzhou Central Hospital
    Zhengzhou, Henan, China
  • Jingzhou Central Hospital
    Jingzhou, Hubei, China
  • Shiyan Renmin Hospital
    Shiyan, Hubei, China
  • Taihe Hospital
    Shiyan, Hubei, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Hunan University of Medicine General Hospital
    Huaihua, Hunan, China
  • Inner Mongolia Baogang Hospital
    Baotou, Inner Mongolia, China
  • The First People's Hospital of Lianyungang
    Lianyungang, Jiangsu, China
  • Suzhou Municipal Hospital
    Suzhou, Jiangsu, China
  • Wuxi People's Hospital
    Wuxi, Jiangsu, China
  • Wuxi Second People's Hospital
    Wuxi, Jiangsu, China
  • The Affiliated Hospital Of Xuzhou Medical University
    Xuzhou, Jiangsu, China
  • Yancheng NO.1 People's Hospital
    Yancheng, Jiangsu, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu, China
  • The First Affiliated Hospital of Gannan Medical University
    Ganzhou, Jiangxi, China
  • The First Hospital of Jilin University
    Changchun, Jilin, China
  • Shenyang Medical College Affiliated Central Hospital
    Shenyang, Liaoning, China
  • Jinan Central Hospital
    Jinan, Shandong, China
  • Jining NO.1 People's Hospital
    Jining, Shandong, China
  • Huashan Hospital, Fudan University
    Shanghai, Shanghai Municipality, China
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai Municipality, China
  • Taiyuan Central Hospital
    Taiyuan, Shanxi, China
  • Chengdu Second People 's Hospital
    Chengdu, Sichuan, China
  • Suining Central Hospital
    Suining, Sichuan, China
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang, China
  • Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
  • The First Hospital of Jiaxing
    Jiaxing, Zhejiang, China
  • The First Affiliated Hospital of NingBo University
    Ningbo, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Aug 2026, 7 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Jan 22, 2026
StartActual
Dec 30, 2025
Primary completionActual
Aug 6, 2026
CompletionActual
Aug 19, 2026
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07357831
Collaborators
MC2 Therapeutics
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Dec 30, 2025
Primary completion
Aug 6, 2026
Completion
Aug 19, 2026
Last update
Aug 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate

Start the discussion